Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 10, 2012, Pages 1211-1220

  Safe, Stephen H ^a,b   Prather, Paul L ^c   Brents, Lisa K ^c   Chadalapaka, Gayathri ^a   Jutooru, Indira ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Downregulation; Reactive oxygen species; Sp transcription factors

Indexed keywords

BARDOXOLONE; BETULIC ACID; BOSWELLIC ACID; CANNABINOID RECEPTOR; CELASTROL; CELL NUCLEUS RECEPTOR; CYCLIN D1; CYCLOOXYGENASE 2 INHIBITOR; DITHIOTHREITOL; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FARNESOID X RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUTATHIONE; GLYCYRRHETINIC ACID; KRUPPEL LIKE FACTOR 4; MELANOCORTIN RECEPTOR; MICRORNA 20A; OLEANOLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEASOME; REACTIVE OXYGEN METABOLITE; SURVIVIN; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRANSCRIPTION FACTOR SP4; TRITERPENOID; UNINDEXED DRUG; URSOLIC ACID; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; COLON CANCER; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; MITOCHONDRIAL MEMBRANE POTENTIAL; NEOPLASM; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION;

ANIMALS; ANTICARCINOGENIC AGENTS; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PENTACYCLIC TRITERPENES;

EID: 84870201236     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012803833099     Document Type: Article

References (107)

1. Pentacyclic Triterpenes as Promising Agents in Cancer; Nova Science Publishers, Inc.: New York, 2010.
2. Alakurtti, S.; Makela, T.; Koskimies, S.; Yli-Kauhaluoma, J. Pharmacological properties of the ubiquitous natural product betulin. Eur. J. Pharm. Sci., 2006, 29, 1.
3. Fulda, S. Betulinic Acid for cancer treatment and prevention. Int. J. Mol. Sci., 2008, 9, 1096.
4. Salvador, J.A.R.; Leal, A.S.M.; Santos, R.C. In Pentacyclic Triterpenes as Promising Agents in Cancer; Salvador, J.A.R., Ed.; Nova Science Publishers, Inc.: New York, 2010, p 191.
5. Salvador, J.A.R.; Moreira, V.M. In Pentacyclic Triterpenes in Promising Agents in Cancer; Salvador, J.A.R., Ed.; Nova Science Publishers, Inc.: New York, 2010, p 249.
6. Safe, S.; Chadalapaka, G.; Jutooru, I.; Chintharlapalli, S.; Papineni, S. In Pentacylic Triterpenes as Promising Agents in Cancer; Salvador, J.A.R., Ed.; Nova Science Publishers, Inc.: New York, 2010, p 277.
7. Liby, K.T.; Yore, M.M.; Sporn, M.B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat. Rev. Cancer, 2007, 7, 357.
8. Hsu, Y.L.; Kuo, P.L.; Lin, L.T.; Lin, C.C. Asiatic acid, a triterpene, induces apoptosis and cell cycle arrest through activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways in human breast cancer cells. J. Pharmacol. Exp. Ther., 2005, 313, 333.
9. Shishodia, S.; Sethi, G.; Konopleva, M.; Andreeff, M.; Aggarwal, B.B. A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemo- therapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin. Cancer Res., 2006, 12, 1828.
10. Pathak, A.K.; Bhutani, M.; Nair, A.S.; Ahn, K.S.; Chakraborty, A.; Kadara, H.; Guha, S.; Sethi, G.; Aggarwal, B.B. Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol. Cancer Res., 2007, 5, 943.
11. Deeb, D.; Gao, X.; Dulchavsky, S.A.; Gautam, S.C. CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells. J. Exp. Ther. Oncol., 2008, 7, 31.
12. Huang, Y.; Zhou, Y.; Fan, Y.; Zhou, D. Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett., 2008, 264, 101.
13. Kunnumakkara, A.B.; Nair, A.S.; Sung, B.; Pandey, M.K.; Aggarwal, B.B. Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol. Cancer Res., 2009, 7, 118.
14. Pandey, M.K.; Sung, B.; Aggarwal, B.B. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int. J. Cancer, 2010, 127, 282.
15. Yuan, H.Q.; Kong, F.; Wang, X.L.; Young, C.Y.; Hu, X.Y.; Lou, H.X. Inhibitory effect of acetyl-11-keto-beta-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. Biochem. Pharmacol., 2008, 75, 2112.
16. Chintharlapalli, S.; Papineni, S.; Ramaiah, S.K.; Safe, S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res., 2007, 67, 2816.
17. Chadalapaka, G.; Jutooru, I.; Burghardt, R.; Safe, S. Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol. Cancer Res., 2010, 8, 739.
18. Chintharlapalli, S.; Papineni, S.; Lei, P.; Pathi, S.; Safe, S. Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors. BMC Cancer, 2011, 11, 371.
19. Chintharlapalli, S.; Papineni, S.; Abdelrahim, M.; Abudayyeh, A.; Jutooru, I.; Chadalapaka, G.; Wu, F.; Mertens-Talcott, S.; Vanderlaag, K.; Cho, S.D.; Smith, R., 3rd; Safe, S. Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano- 3,11-dioxo-18beta-olean-1,12-dien-30-oate in colon cancer cells. Int. J. Cancer, 2009, 125, 1965.
20. Jutooru, I.; Chadalapaka, G.; Abdelrahim, M.; Basha, M.R.; Samudio, I.; Konopleva, M.; Andreeff, M.; Safe, S. Methyl 2- cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a. Mol. Pharmacol., 2010, 78, 226.
21. Safe, S.; Kim, K. Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J. Mol. Endocrinol., 2008, 41, 263.
22. Wu, F.; Xu, R.; Kim, K.; Martin, J.; Safe, S. In vivo profiling of estrogen receptor/specificity protein-dependent transactivation. Endocrinology, 2008, 149, 5696.
23. Abdelrahim, M.; Smith, R., 3rd; Burghardt, R.; Safe, S. Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res., 2004, 64, 6740.
24. Chadalapaka, G.; Jutooru, I.; Chintharlapalli, S.; Papineni, S.; Smith, R., 3rd; Li, X.; Safe, S. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res., 2008, 68, 5345.
25. Abdelrahim, M.; Baker, C.H.; Abbruzzese, J.L.; Sheikh-Hamad, D.; Liu, S.; Cho, S.D.; Yoon, K.; Safe, S. Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res., 2007, 67, 3286.
26. Jutooru, I.; Chadalapaka, G.; Sreevalsan, S.; Lei, P.; Barhoumi, R.; Burghardt, R.; Safe, S. Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp. Cell. Res., 2010, 316, 2174.
27. Jutooru, I.; Chadalapaka, G.; Lei, P.; Safe, S. Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J. Biol. Chem., 2010, 285, 25332.
28. Pathi, S.S.; Jutooru, I.; Chadalapaka, G.; Sreevalsan, S.; Anand, S.; Thatcher, G.R.; Safe, S. GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species- microRNA-27a: ZBTB10-specificity protein pathway. Mol. Cancer Res., 2011, 9, 195.
29. Chintharlapalli, S.; Papineni, S.; Lee, S.O.; Lei, P.; Jin, U.H.; Sherman, S.I.; Santarpia, L.; Safe, S. Inhibition of pituitary tumor- transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins. Mol. Carcinog., 2011, 50, 655.
30. Papineni, S.; Chintharlapalli, S.; Abdelrahim, M.; Lee, S.O.; Burghardt, R.; Abudayyeh, A.; Baker, C.; Herrera, L.; Safe, S. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 2009, 30, 1193.
31. Black, A.R.; Black, J.D.; Azizkhan-Clifford, J. Sp1 and kruppel- like factor family of transcription factors in cell growth regulation and cancer. J. Cell. Physiol., 2001, 188, 143.
32. Ammendola, R.; Mesuraca, M.; Russo, T.; Cimino, F. Sp1 DNA binding efficiency is highly reduced in nuclear extracts from aged rat tissues. J. Biol. Chem., 1992, 267, 17944.
33. Oh, J.E.; Han, J.A.; Hwang, E.S. Downregulation of transcription factor, Sp1, during cellular senescence. Biochem. Biophys. Res. Commun., 2007, 353, 86.
34. Bouwman, P.; Philipsen, S. Regulation of the activity of Sp1- related transcription factors. Mol. Cell. Endocrinol., 2002, 195, 27.
35. Wei, D.; Wang, L.; He, Y.; Xiong, H.Q.; Abbruzzese, J.L.; Xie, K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res., 2004, 64, 2030.
36. Abdelrahim, M.; Safe, S. Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol. Pharmacol., 2005, 68, 317.
37. Abdelrahim, M.; Baker, C.H.; Abbruzzese, J.L.; Safe, S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J. Natl. Cancer Inst., 2006, 98, 855.
38. Konduri, S.; Colon, J.; Baker, C.H.; Safe, S.; Abbruzzese, J.L.; Abudayyeh, A.; Basha, M.R.; Abdelrahim, M. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol. Cancer Ther., 2009, 8, 533.
39. Colon, J.; Basha, M.R.; Madero-Visbal, R.; Konduri, S.; Baker, C.H.; Herrera, L.J.; Safe, S.; Sheikh-Hamad, D.; Abudayyeh, A.; Alvarado, B.; Abdelrahim, M. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest. New Drugs, 2011, 29, 41.
40. Basha, R.; Baker, C.H.; Sankpal, U.T.; Ahmad, S.; Safe, S.; Abbruzzese, J.L.; Abdelrahim, M. Therapeutic applications of NSAIDS in cancer: special emphasis on tolfenamic acid. Front Biosci (Schol Ed), 2011, 3, 797.
41. Maliakal, P.; Abdelrahim, M.; Sankpal, U.T.; Maliakal, C.; Baker, C.H.; Safe, S.; Herrera, L.J.; Abudayyeh, A.; Kaja, S.; Basha, R. Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats. Invest. New Drugs, 2011.
42. Fulda, S.; Kroemer, G. Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov. Today 2009, 14, 885.
43. Costantini, P.; Jacotot, E.; Decaudin, D.; Kroemer, G. Mitochondrion as a novel target of anticancer chemotherapy. J. Natl. Cancer Inst, 2000, 92, 1042.
44. Galluzzi, L.; Larochette, N.; Zamzami, N.; Kroemer, G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene, 2006, 25, 4812.
45. Hoye, A.T.; Davoren, J.E.; Wipf, P.; Fink, M.P.; Kagan, V.E. Targeting mitochondria. Acc. Chem. Res., 2008, 41, 87.
46. Pathi, S.S.; Lei, P.; Sreevalsan, S.; Chadalapaka, G.; Jutooru, I.; Safe, S. Pharmacologic doses of ascorbic acid repress specificity protein (Sp) transcription factors and Sp-regulated genes in colon cancer cells. Nutr. Cancer, 2011, 63, 1133.
47. Lou, Z.; O'Reilly, S.; Liang, H.; Maher, V.M.; Sleight, S.D.; McCormick, J.J. Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res, 2005, 65, 1007.
48. Scott, G.K.; Mattie, M.D.; Berger, C.E.; Benz, S.C.; Benz, C.C. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res, 2006, 66, 1277.
49. Mertens-Talcott, S.U.; Chintharlapalli, S.; Li, X.; Safe, S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA- MB-231 breast cancer cells. Cancer Res, 2007, 67, 11001.
50. Kim, K.; Chadalapaka, G.; Lee, S.O.; Yamada, D.; Sastre-Garau, X.; Defossez, P.A.; Park, Y.Y.; Lee, J.S.; Safe, S. Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene, 2011, 31, 1034.
51. Honda, T.; Gribble, G.W.; Suh, N.; Finlay, H.J.; Rounds, B.V.; Bore, L.; Favaloro, F.G., Jr.; Wang, Y.; Sporn, M.B. Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages. J. Med. Chem., 2000, 43, 1866.
52. Honda, T.; Finlay, H.J.; Gribble, G.W.; Suh, N.; Sporn, M.B. New enone derivatives of oleanolic acid and ursolic acid as inhibitors of nitric oxide production in mouse macrophages. Bioorg. Med. Chem. Lett., 1997, 7, 1623.
53. Honda, T.; Rounds, B.V.; Gribble, G.W.; Suh, N.; Wang, Y.; Sporn, M.B. Design and synthesis of 2-cyano-3,12-dioxoolean-1,9- dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg. Med. Chem. Lett., 1998, 8, 2711.
54. Wang, Y.; Porter, W.W.; Suh, N.; Honda, T.; Gribble, G.W.; Leesnitzer, L.M.; Plunket, K.D.; Mangelsdorf, D.J.; Blanchard, S.G.; Willson, T.M.; Sporn, M.B. A synthetic triterpenoid, 2- cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol. Endocrinol., 2000, 14, 1550.
55. Ikezoe, T.; Miller, C.W.; Kawano, S.; Heaney, A.; Williamson, E.A.; Hisatake, J.; Green, E.; Hofmann, W.; Taguchi, H.; Koeffler, H.P. Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies. Cancer Res., 2001, 61, 5307.
56. Willson, T.M.; Lambert, M.H.; Kliewer, S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu. Rev. Biochem., 2001, 70, 341.
57. Escher, P.; Wahli, W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat. Res., 2000, 448, 121.
58. Fajas, L.; Debril, M.B.; Auwerx, J. Peroxisome proliferator- activated receptor-gamma: from adipogenesis to carcinogenesis. J. Mol. Endocrinol., 2001, 27, 1.
59. Grommes, C.; Landreth, G.E.; Heneka, M.T. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet. Oncol., 2004, 5, 419.
60. Murphy, G.J.; Holder, J.C. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol. Sci., 2000, 21, 469.
61. Chintharlapalli, S.; Papineni, S.; Konopleva, M.; Andreef, M.; Samudio, I.; Safe, S. 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma- dependent and -independent pathways. Mol. Pharmacol., 2005, 68, 119.
62. Mix, K.S.; Coon, C.I.; Rosen, E.D.; Suh, N.; Sporn, M.B.; Brinckerhoff, C.E. Peroxisome proliferator-activated receptor- gamma-independent repression of collagenase gene expression by 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and prostaglandin 15-deoxy-delta(12,14) J2: a role for Smad signaling. Mol. Pharmacol., 2004, 65, 309.
63. Lapillonne, H.; Konopleva, M.; Tsao, T.; Gold, D.; McQueen, T.; Sutherland, R.L.; Madden, T.; Andreeff, M. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res., 2003, 63, 5926.
64. Melichar, B.; Konopleva, M.; Hu, W.; Melicharova, K.; Andreeff, M.; Freedman, R.S. Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression. Gynecol. Oncol., 2004, 93, 149.
65. Konopleva, M.; Elstner, E.; McQueen, T.J.; Tsao, T.; Sudarikov, A.; Hu, W.; Schober, W.D.; Wang, R.Y.; Chism, D.; Kornblau, S.M.; Younes, A.; Collins, S.J.; Koeffler, H.P.; Andreeff, M. Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol. Cancer Ther., 2004, 3, 1249.
66. Tabe, Y.; Konopleva, M.; Kondo, Y.; Contractor, R.; Tsao, T.; Konoplev, S.; Shi, Y.; Ling, X.; Watt, J.C.; Tsutsumi-Ishii, Y.; Ohsaka, A.; Nagaoka, I.; Issa, J.P.; Kogan, S.C.; Andreeff, M. PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL. Cancer Biol. Ther., 2007, 6, 1967.
67. Chadalapaka, G.; Jutooru, I.; McAlees, A.; Stefanac, T.; Safe, S. Structure-dependent inhibition of bladder and pancreatic cancer cell growth by 2-substituted glycyrrhetinic and ursolic acid derivatives. Bioorg. Med. Chem. Lett., 2008, 18, 2633.
68. Chintharlapalli, S.; Papineni, S.; Jutooru, I.; McAlees, A.; Safe, S. Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor {gamma} agonists in colon cancer cells. Mol. Cancer Ther., 2007, 6, 1588.
69. Papineni, S.; Chintharlapalli, S.; Safe, S. Methyl 2-cyano-3,11- dioxo-18 beta-olean-1,12-dien-30-oate is a peroxisome proliferator- activated receptor-gamma agonist that induces receptor- independent apoptosis in LNCaP prostate cancer cells. Mol. Pharmacol., 2008, 73, 553.
70. Chintharlapalli, S.; Papineni, S.; Liu, S.; Jutooru, I.; Chadalapaka, G.; Cho, S.D.; Murthy, R.S.; You, Y.; Safe, S. 2-Cyano-lup-1-en-3- oxo-20-oic acid, a cyano derivative of betulinic acid, activates peroxisome proliferator-activated receptor gamma in colon and pancreatic cancer cells. Carcinogenesis, 2007, 28, 2337.
71. Forman, B.M.; Goode, E.; Chen, J.; Oro, A.E.; Bradley, D.J.; Perlmann, T.; Noonan, D.J.; Burka, L.T.; McMorris, T.; Lamph, W.W.; Evans, R.M.; Weinberger, C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell, 1995, 81, 687.
72. Wang, Y.D.; Chen, W.D.; Moore, D.D.; Huang, W. FXR: a metabolic regulator and cell protector. Cell Res., 2008, 18, 1087.
73. Swales, K.E.; Korbonits, M.; Carpenter, R.; Walsh, D.T.; Warner, T.D.; Bishop-Bailey, D. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res., 2006, 66, 10120.
74. Journe, F.; Durbecq, V.; Chaboteaux, C.; Rouas, G.; Laurent, G.; Nonclercq, D.; Sotiriou, C.; Body, J.J.; Larsimont, D. Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients. Breast Cancer Res. Treat, 2009, 115, 523.
75. Journe, F.; Laurent, G.; Chaboteaux, C.; Nonclercq, D.; Durbecq, V.; Larsimont, D.; Body, J.J. Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation. Breast Cancer Res. Treat, 2008, 107, 49.
76. De Gottardi, A.; Touri, F.; Maurer, C.A.; Perez, A.; Maurhofer, O.; Ventre, G.; Bentzen, C.L.; Niesor, E.J.; Dufour, J.F. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig Dis. Sci., 2004, 49, 982.
77. Lee, J.Y.; Lee, K.T.; Lee, J.K.; Lee, K.H.; Jang, K.T.; Heo, J.S.; Choi, S.H.; Kim, Y.; Rhee, J.C. Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion. Br. J. Cancer, 2011, 104, 1027.
78. Maran, R.R.; Thomas, A.; Roth, M.; Sheng, Z.; Esterly, N.; Pinson, D.; Gao, X.; Zhang, Y.; Ganapathy, V.; Gonzalez, F.J.; Guo, G.L. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J. Pharmacol. Exp. Ther., 2009, 328, 469.
79. Kim, I.; Morimura, K.; Shah, Y.; Yang, Q.; Ward, J.M.; Gonzalez, F.J. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis, 2007, 28, 940.
80. Otte, K.; Kranz, H.; Kober, I.; Thompson, P.; Hoefer, M.; Haubold, B.; Remmel, B.; Voss, H.; Kaiser, C.; Albers, M.; Cheruvallath, Z.; Jackson, D.; Casari, G.; Koegl, M.; Paabo, S.; Mous, J.; Kremoser, C.; Deuschle, U. Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol. Cell. Biol., 2003, 23, 864.
81. Carter, B.A.; Taylor, O.A.; Prendergast, D.R.; Zimmerman, T.L.; Von Furstenberg, R.; Moore, D.D.; Karpen, S.J. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr. Res., 2007, 62, 301.
82. Zhao, C.; Dahlman-Wright, K.; Gustafsson, J.A. Estrogen signaling via estrogen receptor {beta}. J. Biol. Chem., 2010, 285, 39575.
83. Hsu, C.; Hsieh, C.L.; Kuo, Y.H.; Huang, C.J. Isolation and identification of cucurbitane-type triterpenoids with partial agonist/antagonist potential for estrogen receptors from Momordica charantia. J. Agric. Food. Chem., 2011, 59, 4553.
84. DuSell, C.D.; Umetani, M.; Shaul, P.W.; Mangelsdorf, D.J.; McDonnell, D.P. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol. Endocrinol., 2008, 22, 65.
85. Umetani, M.; Domoto, H.; Gormley, A.K.; Yuhanna, I.S.; Cummins, C.L.; Javitt, N.B.; Korach, K.S.; Shaul, P.W.; Mangelsdorf, D.J. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat. Med., 2007, 13, 1185.
86. Ju, Y.H.; Clausen, L.M.; Allred, K.F.; Almada, A.L.; Helferich, W.G. beta-Sitosterol, beta-Sitosterol Glucoside, and a Mixture of beta-Sitosterol and beta-Sitosterol Glucoside Modulate the Growth of Estrogen-Responsive Breast Cancer Cells In Vitro and in Ovariectomized Athymic Mice. J. Nutr., 2004, 134, 1145.
87. Yue, P.; Zhou, Z.; Khuri, F.R.; Sun, S.Y. Depletion of intracellular glutathione contributes to JNK-mediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me). Cancer Biol. Ther., 2006, 5, 492.
88. Muceniece, R.; Saleniece, K.; Riekstina, U.; Krigere, L.; Tirzitis, G.; Ancans, J. Betulin binds to melanocortin receptors and antagonizes alpha-melanocyte stimulating hormone induced cAMP generation in mouse melanoma cells. Cell. Biochem. Funct., 2007, 25, 591.
89. Kawamata, Y.; Fujii, R.; Hosoya, M.; Harada, M.; Yoshida, H.; Miwa, M.; Fukusumi, S.; Habata, Y.; Itoh, T.; Shintani, Y.; Hinuma, S.; Fujisawa, Y.; Fujino, M. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem., 2003, 278, 9435.
90. Maruyama, T.; Miyamoto, Y.; Nakamura, T.; Tamai, Y.; Okada, H.; Sugiyama, E.; Itadani, H.; Tanaka, K. Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun., 2002, 298, 714.
91. Fiorucci, S.; Mencarelli, A.; Palladino, G.; Cipriani, S. Bile-acid- activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol. Sci., 2009, 30, 570.
92. Yasuda, H.; Hirata, S.; Inoue, K.; Mashima, H.; Ohnishi, H.; Yoshiba, M. Involvement of membrane-type bile acid receptor M- BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem. Biophys. Res. Commun., 2007, 354, 154.
93. Hong, J.; Behar, J.; Wands, J.; Resnick, M.; Wang, L.J.; DeLellis, R.A.; Lambeth, D.; Souza, R.F.; Spechler, S.J.; Cao, W. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut, 2010, 59, 170.
94. Genet, C.; Strehle, A.; Schmidt, C.; Boudjelal, G.; Lobstein, A.; Schoonjans, K.; Souchet, M.; Auwerx, J.; Saladin, R.; Wagner, A. Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes. J. Med. Chem., 2010, 53, 178.
95. Barroso-Gonzalez, J.; El Jaber-Vazdekis, N.; Garcia-Exposito, L.; Machado, J.D.; Zarate, R.; Ravelo, A.G.; Estevez-Braun, A.; Valenzuela-Fernandez, A. The lupane-type triterpene 30-oxo- calenduladiol is a CCR5 antagonist with anti-HIV-1 and anti- chemotactic activities. J. Biol. Chem., 2009, 284, 16609.
96. Guzman, M. Cannabinoids: potential anticancer agents. Nat. Rev. Cancer, 2003, 3, 745.
97. Bifulco, M.; Laezza, C.; Gazzerro, P.; Pentimalli, F. Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review). Oncol. Rep., 2007, 17, 813.
98. Velasco, G.; Carracedo, A.; Blazquez, C.; Lorente, M.; Aguado, T.; Haro, A.; Sanchez, C.; Galve-Roperh, I.; Guzman, M. Cannabinoids and gliomas. Mol. Neurobiol., 2007, 36, 60.
99. Sarfaraz, S.; Adhami, V.M.; Syed, D.N.; Afaq, F.; Mukhtar, H. Cannabinoids for cancer treatment: progress and promise. Cancer Res., 2008, 68, 339.
100. Flygare, J.; Sander, B. The endocannabinoid system in cancer- potential therapeutic target? Semin. Cancer Biol., 2008, 18, 176.
101. Bernadette, H. Cannabinoid therapeutics: high hopes for the future. Drug Discov.Today,2005, 10, 459.
102. Hall, W.; Christie, M.; Currow, D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet. Oncol., 2005, 6, 35.
103. da Silva, K.A.; Paszcuk, A.F.; Passos, G.F.; Silva, E.S.; Bento, A.F.; Meotti, F.C.; Calixto, J.B. Activation of cannabinoid receptors by the pentacyclic triterpene alpha,beta-amyrin inhibits inflammatory and neuropathic persistent pain in mice. Pain, 2011, 152, 1872.
104. Melo, C.M.; Morais, T.C.; Tome, A.R.; Brito, G.A.; Chaves, M.H.; Rao, V.S.; Santos, F.A. Anti-inflammatory effect of alpha,beta- amyrin, a triterpene from Protium heptaphyllum, on cerulein- induced acute pancreatitis in mice. Inflamm. Res., 2011, 60, 673.
105. Santos, E.N.; Lima, J.C.; Noldin, V.F.; Cechinel-Filho, V.; Rao, V.S.; Lima, E.F.; Schmeda-Hirschmann, G.; Sousa, P.T., Jr.; Martins, D.T. Anti-inflammatory, antinociceptive, and antipyretic effects of methanol extract of Cariniana rubra stem bark in animal models. An. Acad. Bras. Cienc., 2011, 83, 557.
106. Oliveira, F.A.; Lima-Junior, R.C.; Cordeiro, W.M.; Vieira-Junior, G.M.; Chaves, M.H.; Almeida, F.R.; Silva, R.M.; Santos, F.A.; Rao, V.S. Pentacyclic triterpenoids, alpha,beta-amyrins, suppress the scratching behavior in a mouse model of pruritus. Pharmacol. Biochem. Behav., 2004, 78, 719.
107. Barros, F.W.; Bandeira, P.N.; Lima, D.J.; Meira, A.S.; de Farias, S.S.; Albuquerque, M.R.; dos Santos, H.S.; Lemos, T.L.; de Morais, M.O.; Costa-Lotufo, L.V.; Pessoa Cdo, O. Amyrin esters induce cell death by apoptosis in HL-60 leukemia cells. Bioorg. Med. Chem., 2011, 19, 1268.